Skip to main content
Evon Medics logo

Evon Medics

Ellicott City, Maryland

  • Digital therapeutics
  • Seed
  • Alzheimer's and dementia

Evon Medics is a neurotechnology company developing medical devices and digital therapeutics to support brain health and address neurological conditions. Its technologies use olfactory stimulation and brain-training programs for applications including cognitive decline, substance use disorders, and chronic pain.

Raised
$23.1M
Latest round
Seed
Investors
3
Employees
11–50

reccy insights

Recent highlights

On September 2, 2026, Evon Medics announced that MemoryDriver would relaunch on September 15 with a national “Beat the Clock” navigation challenge. The company describes MemoryDriver as a free navigation-based cognitive-training app, extending its work beyond clinical and therapeutic products into a consumer-facing brain-training experience. On March 25, 2026, Evon Medics publicized COAT-related data reporting improved cognition and changes in gray matter in brain regions associated with Alzheimer’s disease. These are company-reported findings and do not, on their own, establish clinical effectiveness. Earlier milestones include four disclosed grants between April 2021 and May 2023 totaling $11,620,064, with support associated with the National Institute on Aging, the National Institute on Drug Abuse, and the National Institute of Neurological Disorders and Stroke. In September 2022, co-founder Dr. Evaristus Nwulia was appointed director and principal investigator of the NeuroTech Harbor Technology Accelerator. The available company updates emphasize product development and research; no partnerships or awards are identified in the available profile information.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Evon Medics distinct

  1. 01Develops olfactory-based brain stimulation and training technologies grounded in neuroscience research.
  2. 02Targets applications including Alzheimer’s disease, substance use disorders, and chronic pain.
  3. 03Combines medical devices with digital therapeutics and remote patient-management capabilities.
  4. 04Its COAT clinical study reported promising cognitive and brain-health outcomes in people with mild cognitive impairment.
  5. 05MemoryDriver is presented as the company’s first commercially available product.

Technology & products6

  • COAT™ (Computerized Olfactory Adaptive Training)

    A non-invasive, home-based olfactory training system for cognitive support in people with mild cognitive impairment and early Alzheimer’s disease.

  • Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)

    A home-based chemosensory training system under development for substance use disorder and chronic pain applications.

  • MemoryDriver™

    A brain-training application with navigation-based exercises intended to support memory, spatial navigation, focus, and cognitive performance.

Recent updates2

  • Sep 2, 2026Product launch

    Evon Medics announced a September 15, 2026 relaunch of MemoryDriver, a free cognitive-training navigation app, alongside a national navigation competition.

    prnewswire.com
  • Feb 2026Product launch

    Evon Medics Officially Launches MemoryDriver™ 1.0

    youtu.be

Funding

$23.1M disclosed
3 investors

Similar companies

About Evon Medics

Products
COAT™ (Computerized Olfactory Adaptive Training), Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), MemoryDriver™, EDITOR, CBOT-P, Evon Medics Rapid Smell Test (EMRAST)
Leadership
Charles Nwaokobia, Chief Operating Officer
Focus areas
Neurotechnology, neurology, brain health, digital therapeutics, medical devices, alzheimer s disease, cognitive training, remote patient monitoring
Headquarters
Ellicott City, Maryland
Employees
11–50
Patents granted
5
Trademarks
3